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Pharmacogenomics is moving from a candidate gene strategy to large scale approaches.
This is in line with the new paradigm of linking a trait to (a) pathway(s) rather than to single
genes. In addition, breakthroughs in genomics offer a non-a priori assessment of impli-
cated genes, expanding the possibilities in pharmacogenomics research. In this review,
we discuss the pros and cons of new concepts in study design and on high throughput
approaches to be implemented in the near future.
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INTRODUCTION
The concept that phenotypic traits are controlled by a single gene
proved true for Mendelian diseases (Nebert et al., 2008). A simi-
lar paradigm applies to pharmacology: the single gene approach
was useful for the understanding of quantitative traits charac-
terized by a bimodal distribution, such as the metabolism of
the antituberculosis drug isoniazid through N -acetyltransferase
(Kinzig-Schippers et al., 2005), and the association of HLA∗B5701
with the hypersensitivity reaction to the antiretroviral drug aba-
cavir (Mallal et al., 2008).Where applicable, single gene association
is a cost–effective and efﬁcient approach in pharmacogenetics. On
the other hand, since this particular approach relies on an a pri-
ori hypothesis of the implicated gene, it may be reductionist and
may often result in non-replication of the ﬁndings across different
studies; a well-known example is the genetic variation in the drug
transporter ABCB1 and its effect in drug disposition (Leschziner
et al., 2007).
Most diseases and phenotypic traits are thought to result from
the interplay of several genes with environmental factors. Here,
large scale candidate gene analyses aim at understanding the inter-
actions among several genes and how these contribute to a par-
ticular trait. This strategy involves investigation of genes encoding
proteins potentially involved in a given phenotype according to
their described or supposed function. This is in line with the new
paradigm of linking a trait to a pathway rather than to a single
gene, but in return it does not allow an in-depth analysis of the
investigated genes (Nebert et al., 2008; Lubomirov et al., 2010). In
addition, like for single candidate gene analysis, there is an a priori
hypothesis of the implicated genes.
Today, the new concept of study design that relies on a non-
a priori assessment of implicated genes is applied in genome-wide
association studies. In this review we discuss the pros and cons of
this approach and other high throughput approaches likely to be
used for pharmacogenomics research in the near future.
GENOME-WIDE ASSOCIATION STUDIES AND
PHARMACOGENOMICS
The genome-wide association study (GWAS) approach aims at dis-
covering new biological pathways and further our understanding
of complex phenotypic traits. This strategy consists in screening
the genome to identify genetic variants associatedwith a givenphe-
notype using high coverage genotyping arrays [from100,000 to 2.3
million single nucleotide polymorphisms (SNPs) per array]. The
essential genomic feature used in the design of GWAS arrays is that
genetic variants are inherited together forming haplotypes (Inter-
national HapMap Consortium, 2003). This characteristic allows
assessment of SNPs that tag a haplotype (tag SNP) instead of geno-
typing all variants present in the haplotype. In return, tag SNPs
do not necessarily allow the identiﬁcation of the causal variant(s)
responsible for the phenotypic trait (Figure 1).
Genome-wide association study approaches have been used for
identiﬁcation of genetic loci associated with disease susceptibility
(Hindorff et al., 2009), and they are now applied to pharmacoge-
nomics (Daly, 2010; Wang et al., 2011). Some studies conﬁrmed
previous results such as the association of variants in the genes
CYP2C9,VKORC1, andCYP4F2 with the need of dose adjustment
for the anticoagulant drug warfarin (Cooper et al., 2008; Takeuchi
et al., 2009; Cha et al., 2010) and the decreased antiplatelet effect
of clopidogrel with a genetic variant in CYP2C19 (Shuldiner
et al., 2009). Other studies discovered new associations such as
the enhanced risk of simvastatin-induced myopathy associated
with the presence of the allele SLCO1B1∗5 (Link et al., 2008), the
drug associated liver injury of the antibiotic ﬂucloxacillin with the
presence of the allele HLA∗B5701 (Daly et al., 2009) and ﬁnally,
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FIGURE 1 | Current pipeline used in pharmacogenomics.
fourGWAShave demonstrated that hepatitis C treatment-induced
clearance was strongly dependent of genetic variants in IL28B, a
gene encoding for the interferon-λ3. Two SNPs (rs12979860 and
rs8099917) were signiﬁcantly associated with response to pegy-
lated interferon alpha and ribavirin in patients chronically infected
with hepatitis C virus (HCV) genotype 1 (Ge et al., 2009; Suppiah
et al., 2009; Tanaka et al., 2009; Rauch et al., 2010).
In summary, GWAS represent a breakthrough in the under-
standing of complex phenotypic traits. However, the SNPs identi-
ﬁed in these studies as associated with the study phenotypes (hit
SNPs) are not necessarily the causal variants. Therefore, compre-
hensive resequencing and functional analyses are needed tonarrow
down on the causal variants.
RESEQUENCING AS A STRATEGY TO IMPROVE
PHARMACOGENOMIC STUDIES
Resequencing aims at identifying the causal variant if the SNPs
identiﬁed in the GWAS (hit SNPs) are unlikely to be functional
(e.g., SNPs localized in intergenic regions). One approach consists
in resequencing the chromosomic region of interest in individu-
als representing concordant and discordant genotype–phenotype
associations. “Concordant” is deﬁned in individuals homozygous
for the rare allele of the hit SNP that present the associated phe-
notype, or in individuals that neither have the rare allele of the
hit SNP nor the associated phenotype. “Discordant” is deﬁned in
individuals homozygous for the rare allele of the hit SNP without
the study phenotype, or in individuals without the rare allele of the
hit SNP but presenting the study phenotype. Haplotype inference
in these individuals with extreme phenotype–genotype combina-
tions allows the identiﬁcation of genetic variants tagged by the hit
SNP. The causal variants are expected to be as frequent as, or more
frequent than the hit SNP in concordant individuals and/or less
frequent in discordant individuals (Figure 1).
This approach has been successfully applied in an ADME phar-
macogenetics study of the antiretroviral drug lopinavir coformu-
lated with ritonavir (LPV/r). In this study, two of the hit SNPs
associated with LPV/r clearance were located in SLCO1B1. One
SNPwas known to be a functional variant (rs4149056), the second
was a tagSNP. Resequencing and haplotype inference identiﬁed a
SNP leading to a non-synonymous amino acid change likely to be
responsible for the detected effect (rs11045819; Lubomirov et al.,
2010). The same approach aimed at determining the functional
variant in IL28B that associates with HCV treatment and infec-
tion outcomes, and that is tagged by an intergenic SNP, rs8099917
(Suppiah et al., 2009; Tanaka et al., 2009; Rauch et al., 2010).
Two distinct families of haplotypes and four candidate causal
SNPs were identiﬁed on the basis of allelic frequency, genome
location, and linkage disequilibrium pattern (Rauch et al., 2010).
Haplotypes carrying rs8103142, one of the four candidate SNPs,
increased the predictive value of HCV infection outcome, in com-
parison to the tag SNP rs8099917, initially identiﬁed in the GWAS
(di Iulio et al., 2011).However, these haplotypes were highly linked
to rs12979860, a tag SNP identiﬁed in other studies (Ge et al., 2009;
Thomas et al., 2009) that had comparable predictive value,making
the assignment of the true causal variant difﬁcult.
In summary, resequencing approaches can identify the poten-
tial causal variant associated with a phenotype. However, func-
tional analyses are still needed to assess themechanismof action. In
addition, since this strategy used non-automated, labor-intensive
techniques, it can only be applied to small number of samples.
This inconvenient may be solved by high throughput sequencing
techniques.
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FIGURE 2 |Time line in the genomics/pharmacogenomics field.
HOW CAN HIGH THROUGHPUT SEQUENCING BE USEFUL IN
PHARMACOGENOMIC STUDIES?
The expanding possibilities offered since the completion of the
Human Genome Project1, the International HapMap Consor-
tium (2003, 2005), and the 1000 Genomes Project Consortium
(2010) together with the availability of new high throughput
sequencing technologies, are the bases for future initiatives in
pharmacogenomics.
High throughput sequencing allows whole genome/exome/
transcriptome analyses. Variants can be identiﬁed independently
of: (I) patterns of linkage dysequilibrium and tag SNPs; specif-
ically, there is no need to customize the arrays according to the
population studied (e.g., variants in African ancestry genomes are
more difﬁcult to tag because of higher recombination rates 2003,
2005); and (II) allelic frequency; it is thought that variants with
high effect sizes will be rare as they may be more deleterious at a
population level (Manolio et al., 2009).
High throughput sequencing can be performed either at the
DNA or at the RNA level. RNA sequencing has the advantage to
provide qualitative and quantitative information (genetic varia-
tion, gene expression, and alternative splicing). This is important
since gene expression and alternative splicing are more directly
correlated with the phenotype (Ozsolak and Milos, 2011).
In pharmacogenomics, high throughput sequencing may be
very useful as changes in gene expression or splicing are important
for drug disposition (Marez et al., 1995; Chou et al., 2001; Kuehl
et al., 2001; Pitarque et al., 2001; Lang et al., 2004; Menard et al.,
2011). However, the high cost and complexity of data analyses
delay the implementation of this approach.
THE USEFULNESS OF THE NEXT “OMICS”: PROTEOMICS IN
PHARMACOGENOMIC STUDIES
The Human Proteome Project intends to create a comprehen-
sive and public available map of the entire human proteome
(Legrain et al., 2011) through mass spectrometry technology, a
1http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml
highly reproducible technique (Nilsson et al., 2010). Proteomics
aims at studying the function and structure of proteins at large
scale. It allows direct assessment of the abundance of main or
rare isoforms. Proteomics is now on the early phase; evidence of
expression at the protein level is still lacking for about 30% of the
genes of the human genome2.
Speciﬁc to pharmacogenomics, proteomics may be essential
in the identiﬁcation of new players involved not only in drug
pharmacokinetics but also pharmacodynamics. However, the cell
proteome approach will be more challenging than the genome
approach: the cell proteome is very dynamic (proteins are tissue
speciﬁc and change over time), post-transcriptional modiﬁcations
may affect protein function and splicing may result in isoforms
with altered activity.
CONCLUSION
Breakthroughs in genomics inﬂuence pharmacogenomics studies
(Figure 2). It is expected that pharmacogenomics will facilitate
the deployment of personalizedmedicine and individualized drug
therapy. The ﬁeld now moves from the candidate gene strategies
to larger scale approaches, including resequencing of candidate
regions and high throughput exome/genome sequencing. The
complexity of data handling and analysis will be a major difﬁculty
to overcome, and functional studies will be required to decipher
the underlying molecular mechanisms.
GLOSSARY
• Pharmacogenetics: the study of how genetic variation in a single
gene inﬂuences drug pharmacokinetics/pharmacodynamics.
• Pharmacogenomics: the study of how genetic variation
throughout the genome inﬂuences drug pharmacokinet-
ics/pharmacodynamics (same than pharmacogenetics but in
large scale).
2http://web.expasy.org/docs/swiss-prot_guideline.html
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• Single nucleotide polymorphism: variation between members
of the same species of a single nucleotide at a deﬁned posi-
tion in the genome, and occurring at a frequency higher
than 1%.
• Genotype: the genetic background of a given individual.
• Phenotype: individual feature that canbemeasuredor observed.
It is inﬂuenced by the genotype and different environmental
factors.
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